How Familiar Are You With This Emerging Biotech?
The key to finding the best opportunities? Look at where some of the biggest names in the biotech industry going & what therapies are they looking to bring to market? Pay close attention to revenue opportunities that exist for these therapies. These revenue opportunities could make such industry leaders choose to join a specific company.
GT Biopharma Inc. (GTBP) to Present at Roth Capital Partners 30th Annual Conference
GT Biopharma Inc. (GTBP) (Euronext Paris: GTBP.PA) today announced that Shawn Cross, Chairman and Chief Executive Officer, and Raymond Urbanski, Chief Medical Officer, will present a company overview at the Roth Capital Partners 30th Annual Conference on Tuesday, March 13, at 11:30 a.m. PT.
ImmunoGen, Inc. (NASDAQ:IMGN) Reports Significant Operational And Financial Progress In 2017
ImmunoGen, Inc. (NASDAQ:IMGN) has reported significant progress in its 2017 operational results. The company, which is charged with the expansion of the field of antibody-drug conjugates (ADCs) says that it has had strong execution of results within four consecutive quarters. According to ImmunoGen’s president and chief executive officer, Mark Enyedy, the clinical-stage biotech’s battle was not only about making a profit but also paying off the various debts it had incurred.